Cargando…
A Patient with Metastatic Microsatellite Instability-High Pancreatic Ductal Adenocarcinoma with a Prolonged Response to Single-Agent Pembrolizumab
Immunotherapy is an effective new approach in the treatment of many malignancies. However, pancreatic ductal adenocarcinoma (PDAC) does not usually respond to immunotherapy. We discuss the case of a patient with metastatic microsatellite instability-high PDAC who had a prolonged response to single-a...
Autores principales: | Guedikian, Annie A., Randall, Megan E., Sharko, Anita, Leslie, William T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543311/ https://www.ncbi.nlm.nih.gov/pubmed/34720950 http://dx.doi.org/10.1159/000519181 |
Ejemplares similares
-
Irrelevance of Microsatellite Instability in the Epidemiology of Sporadic Pancreatic Ductal Adenocarcinoma
por: Laghi, Luigi, et al.
Publicado: (2012) -
Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications
por: Luchini, Claudio, et al.
Publicado: (2021) -
An Excellent Response of Microsatellite Instability-High Pancreatic Adenocarcinoma to Pembrolizumab Treatment: The Role of Circulating Tumor DNA Testing
por: Anisetti, Bhrugun, et al.
Publicado: (2023) -
Pembrolizumab for a patient with metastatic castration‐resistant prostate cancer with microsatellite instability‐high
por: Fujiwara, Motohiro, et al.
Publicado: (2020) -
Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma
por: Christenson, Eric S., et al.
Publicado: (2022)